BR112023003473A2 - Compostos de carbamato de alquil fenila para o uso na prevenção ou no tratamento de doença neurodegenerativa - Google Patents
Compostos de carbamato de alquil fenila para o uso na prevenção ou no tratamento de doença neurodegenerativaInfo
- Publication number
- BR112023003473A2 BR112023003473A2 BR112023003473A BR112023003473A BR112023003473A2 BR 112023003473 A2 BR112023003473 A2 BR 112023003473A2 BR 112023003473 A BR112023003473 A BR 112023003473A BR 112023003473 A BR112023003473 A BR 112023003473A BR 112023003473 A2 BR112023003473 A2 BR 112023003473A2
- Authority
- BR
- Brazil
- Prior art keywords
- phenyl carbamate
- alkyl phenyl
- prevention
- treatment
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSTOS DE CARBAMATO DE ALQUIL FENILA PARA USO NA PREVENÇÃO OU NO TRATAMENTO DE DOENÇA NEURODEGENERATIVA. A presente invenção refere-se a um composto de carbamato de alquil fenila para o uso na prevenção ou no tratamento de doenças neurodegenerativas. O composto de carbamato de alquil fenila da presente invenção preveniu a perda neuronal dopaminérgica, a ativação atenuada de astrócito/microglia, reprimiu a alfa-sinucleína fosforilada e regulou os níveis de fosforilação de tau e os níveis de acetilação de alfa-tubulina no modelo animal do mal de Parkinson. Além disso, o composto de carbamato de alquil fenila da presente invenção reduziu a proteína de precursor de Amiloide-beta e Amiloide-beta. Portanto, o composto de carbamato de alquil fenila da presente invenção pode ser usado eficazmente para a prevenção ou o tratamento de doenças neurodegenerativas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063072855P | 2020-08-31 | 2020-08-31 | |
| PCT/KR2021/011508 WO2022045824A1 (en) | 2020-08-31 | 2021-08-27 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023003473A2 true BR112023003473A2 (pt) | 2023-04-11 |
Family
ID=80355508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023003473A BR112023003473A2 (pt) | 2020-08-31 | 2021-08-27 | Compostos de carbamato de alquil fenila para o uso na prevenção ou no tratamento de doença neurodegenerativa |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11931332B2 (pt) |
| EP (1) | EP4204395A1 (pt) |
| JP (1) | JP2023539291A (pt) |
| KR (1) | KR20230044274A (pt) |
| CN (1) | CN115996905A (pt) |
| BR (1) | BR112023003473A2 (pt) |
| CA (1) | CA3191072A1 (pt) |
| WO (1) | WO2022045824A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11896593B2 (en) | 2020-09-10 | 2024-02-13 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998380A (en) | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
| JP4320089B2 (ja) | 1999-07-06 | 2009-08-26 | あすか製薬株式会社 | フェニルスルファメート誘導体 |
| PL364680A1 (en) * | 2001-02-27 | 2004-12-13 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| KR20110049901A (ko) * | 2004-10-15 | 2011-05-12 | 얀센 파마슈티카 엔.브이. | 신경변성 질환 치료에 사용하는 카바메이트 화합물 |
| US20090247616A1 (en) | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| WO2014097137A2 (en) * | 2012-12-18 | 2014-06-26 | Mahesh Kandula | Compositions and methods for the treatment of seizures and neurologic diseases |
| WO2014142477A1 (en) * | 2013-03-12 | 2014-09-18 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating pediatric epilesy and epilesy-related syndromes |
| CN105189451A (zh) * | 2013-03-12 | 2015-12-23 | 比皮艾思药物研发有限公司 | 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物 |
| ES2706184T3 (es) | 2013-12-12 | 2019-03-27 | Bio Pharm Solutions Co Ltd | Compuesto derivado de sulfamato para su uso en la prevención o el tratamiento de la epilepsia |
| WO2016190638A1 (ko) * | 2015-05-22 | 2016-12-01 | 에스케이바이오팜 주식회사 | 카리스바메이트를 포함하는 약제, 및 통증 또는 뇌전증을 예방, 경감 또는 치료하기 위한 그의 용도 |
| EP3423433A4 (en) | 2016-02-29 | 2019-12-25 | Bio-Pharm Solutions Co., Ltd. | SULFAMATE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
| US11896593B2 (en) | 2020-09-10 | 2024-02-13 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder |
-
2021
- 2021-08-27 WO PCT/KR2021/011508 patent/WO2022045824A1/en unknown
- 2021-08-27 CN CN202180053744.8A patent/CN115996905A/zh active Pending
- 2021-08-27 EP EP21862120.9A patent/EP4204395A1/en active Pending
- 2021-08-27 CA CA3191072A patent/CA3191072A1/en active Pending
- 2021-08-27 JP JP2023513685A patent/JP2023539291A/ja active Pending
- 2021-08-27 KR KR1020237006812A patent/KR20230044274A/ko unknown
- 2021-08-27 BR BR112023003473A patent/BR112023003473A2/pt unknown
- 2021-08-30 US US17/461,695 patent/US11931332B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023539291A (ja) | 2023-09-13 |
| KR20230044274A (ko) | 2023-04-03 |
| WO2022045824A1 (en) | 2022-03-03 |
| CN115996905A (zh) | 2023-04-21 |
| EP4204395A1 (en) | 2023-07-05 |
| US11931332B2 (en) | 2024-03-19 |
| US20220062220A1 (en) | 2022-03-03 |
| CA3191072A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | From rapid to delayed and remote postconditioning: the evolving concept of ischemic postconditioning in brain ischemia | |
| Yang et al. | IGF-1 protects retinal ganglion cells from hypoxia-induced apoptosis by activating the Erk-1/2 and Akt pathways | |
| US7820640B2 (en) | Methods for treating hearing loss | |
| BR112023003473A2 (pt) | Compostos de carbamato de alquil fenila para o uso na prevenção ou no tratamento de doença neurodegenerativa | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BRPI0819081A8 (pt) | Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento | |
| BR0316397A (pt) | Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral | |
| CZ2002989A3 (cs) | Léčivo k profylaxi a oąetřování neuropatických bolestí | |
| BR112022023366A2 (pt) | Vacina com múltiplos epítopos para o tratamento de mal de alzheimer | |
| BRPI0013010B8 (pt) | formulação aquosa de cloreto de sódio de moxifloxacina, processo para sua preparação e aplicação da referida formulação, bem como preparado de combinação e aplicação de uma solução aquosa de cloridrato de moxifloxacina | |
| BR0210391A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
| BR112022021823A2 (pt) | Métodos para tratar doenças associadas à mielina e doenças associadas à mitocôndria | |
| BR112022022889A2 (pt) | Oligômeros antissentido de opa1 para tratamento de condições e doenças | |
| BR112022017189A2 (pt) | Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1 | |
| Kim et al. | Nucleocytoplasmic p27Kip1 export is required for ERK1/2-mediated reactive astroglial proliferation following status epilepticus | |
| CL2020002317A1 (es) | Compuesto inhibidor de tirosina quinasa c-abl: modalidades y métodos de fabricación y uso | |
| Kast et al. | Glioblastoma treatment using perphenazine to block the subventricular zone’s tumor trophic functions | |
| BR112015023806A2 (pt) | Novos regimes de dosagem de celgosivir para o tratamento de dengue | |
| BR0312929A (pt) | Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo | |
| BR112021025558A2 (pt) | Formulação estável de cetrorelix e processo para a preparação de uma formulação estável | |
| BR112021018724A8 (pt) | "inibidores de pi4-cinase e métodos de usar os mesmos | |
| Hogaboom et al. | Concerted phosphorylation of endogenous tracheal smooth muscle membrane proteins by Ca2+· calmodulin-, cyclic GMP-and cyclic AMP-dependent protein kinases | |
| Young et al. | The relation of the chemical constitution of certain organic arsenical compounds to their action on the optic tract | |
| BR0215336A (pt) | Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica | |
| Ivo et al. | Woman in grey: hydroxychloroquine-induced hyperpigmentation |